KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Common Equity (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Common Equity data on record, last reported at $18.7 billion in Q4 2025.

  • For Q4 2025, Common Equity rose 13.75% year-over-year to $18.7 billion; the TTM value through Dec 2025 reached $18.7 billion, up 13.75%, while the annual FY2025 figure was $18.7 billion, 13.75% up from the prior year.
  • Common Equity reached $18.7 billion in Q4 2025 per VRTX's latest filing, up from $17.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $18.7 billion in Q4 2025 and bottomed at $9.0 billion in Q1 2021.
  • Average Common Equity over 5 years is $14.3 billion, with a median of $15.1 billion recorded in 2023.
  • Peak YoY movement for Common Equity: surged 38.98% in 2021, then dropped 11.05% in 2025.
  • A 5-year view of Common Equity shows it stood at $10.1 billion in 2021, then surged by 37.75% to $13.9 billion in 2022, then increased by 26.36% to $17.6 billion in 2023, then decreased by 6.66% to $16.4 billion in 2024, then grew by 13.75% to $18.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $18.7 billion in Q4 2025, $17.3 billion in Q3 2025, and $17.2 billion in Q2 2025.